Lupin gets U.S. FDA approval for Sugammadex Injection.

Lupin gets U.S. FDA approval for Sugammadex Injection. The company has launched the generic version of the drug in the U.S. market, which is used during anesthesia. This approval expands Lupin’s presence in the U.S. specialty generics segment. The product has $XX million in annual sales, offering near-term revenue potential.

📊 STOCKS: $LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDA